Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event (Notes)

v2.4.0.8
Subsequent Event (Notes)
9 Months Ended
Sep. 30, 2013
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
14.
SUBSEQUENT EVENT
In October 2013, the Company entered into a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by Transgenomic. Under the terms of the strategic collaboration agreement, the Company will be responsible for all U.S.-based marketing and promotion of CardioPredict™, while Transgenomic will be responsible for processing CardioPredict™ in its state-of-the-art CLIA lab and all customer support. Both parties will bear the cost of their respective expenses and will split profit on a formula basis. In addition, the Company will provide Transgenomic with funding support of up to 3.0 million, principally to mitigate working capital requirements.